Early Life and Education
Hubertus von Baumbach, born in either 1966 or 1967, is a scion of the von Baumbach family, whose wealth is intertwined with the pharmaceutical giant Boehringer Ingelheim. His family's involvement traces back to the company's founding in 1885 by Albert Boehringer. Von Baumbach's educational background includes a law degree from the Ludwig-Maximilians-Universität in Munich and an MBA from the Sloan School of Management at MIT.
Rise to Success
Von Baumbach's career at Boehringer Ingelheim began in 2001. He climbed the ranks, serving as Chief Financial Officer from 2009. In 2016, he was appointed Chairman of the Board of Managing Directors, becoming the first family member to lead the company in 25 years. During his tenure, he spearheaded the largest acquisition in the company's history, an asset swap deal. He was also part of Chancellor Angela Merkel's delegation on three state visits to China.
Key Business Strategies
Under von Baumbach's leadership, Boehringer Ingelheim has maintained its focus on research and development, particularly in respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system. As a privately held company, it is able to pursue a long-term vision. The company is dedicated to discovering, developing, manufacturing, and marketing innovative healthcare products. In 2025, he stepped down as CEO and became Chairman of the Shareholders' Committee.
Philanthropy
Boehringer Ingelheim, under von Baumbach’s leadership, focuses on long-term and sustainable action. The company's mission is to create breakthrough therapies where the medical need is high, transforming lives for generations.
